BAY 94-8862 is a novel, non-steroidal, mineralocorticoid receptor antagonist with greater selectivity than spironolactone and stronger mineralocorticoid receptor binding affinity than eplerenone. The aims of the MinerAlocorticoid Receptor Antagonist Tolerability Study (ARTS; NCT01345656) are to evaluate the safety and tolerability of BAY 94-8862 in patients with heart failure associated with a reduced left ventricular ejection fraction (HFREF) and chronic kidney disease (CKD), and to examine the effects on biomarkers of cardiac and renal function.
Introduction
In patients hospitalized for heart failure (HF), high levels of aldosterone are an important predictor of early re-hospitalization. 1, 2 The effects of aldosterone are mediated via activation of its specific nuclear hormone receptor, the mineralocorticoid receptor (MR).
Mineralocorticoid receptor antagonists (MRAs) have been found to be effective in reducing total mortality as well as frequency of hospitalizations for HF in: patients with chronic HF associated with a reduced left ventricular ejection fraction (HFREF); patients with HFREF following myocardial infarction; and patients with mild symptoms of HFREF. 2 -5 MRAs have also been shown to lower blood pressure in patients with primary aldosteronism and individuals with essential hypertension, especially in those with resistant hypertension. 6, 7 Several studies have demonstrated that addition of an MRA to conventional therapy [an angiotensinconverting enzyme (ACE) inhibitor and/or an angiotensin receptor blocker (ARB)] in patients with chronic kidney disease (CKD) substantially reduces proteinuria compared with conventional therapy alone. 8 -11 Reductions in markers of myocardial fibrosis have also been observed in patients receiving MRAs in combination with ACE inhibitors or ARBs. 12 However, the use of MRAs in eligible patients remains suboptimal. 13 -15 The reluctance of some clinicians to use the available MRAs, spironolactone and eplerenone, in HFREF despite their proven effects on mortality is largely attributable to their fear of inducing hyperkalaemia, especially in patients with concomitant diabetes mellitus and/or CKD. The use of spironolactone (a firstgeneration MRA) is also limited by significant progestogenic and antiandrogenic activity owing to its structural similarity to progesterone; 16, 17 this activity has been associated with the occurrence of breast pain in both sexes, gynaecomastia and impotence in males, and menstrual irregularities in females. 4, 18 Eplerenone (a secondgeneration MRA) is more specific for the MR than spironolactone, but the results of two head-to-head comparator studies in patients with hypertension suggest that eplerenone may have reduced antihypertensive efficacy compared with spironolactone. 19, 20 These limitations of spironolactone and eplerenone have stimulated further research, leading to the discovery of new non-steroidal MRAs that are more selective for the MR than spironolactone and have greater affinity for the MR than eplerenone. 21, 22 To reduce the risk of hyperkalaemia, a next-generation MRA is needed that has more pronounced cardiac activity in comparison with the available steroidal MRAs, so that improvements in cardiac function can be achieved without deleterious changes to sodium -potassium homeostasis in the kidney. Such a compound could result in MRAs being used in a larger number of patients with HF and CKD, as well as in other indications such as acute HF syndromes, 23 thereby potentially reducing cardiovascular mortality, hospitalizations for HF, and healthcare resource use.
BAY 94-8862 is a novel, non-steroidal, next-generation MRA.
22
In vitro studies indicate that BAY 94-8862 has superior selectivity compared with spironolactone and improved affinity for the MR compared with eplerenone ( Values were determined using Chinese hamster ovary (CHO)-K1 cells stably expressing the ligand-binding domains of the oxo-steroid receptors. Data were obtained from at least four independent experiments performed in duplicate, except for the oestrogen receptor data, which were obtained from two independent experiments. The respective steroid hormone cell lines and assay procedures have been described previously. 25 EC 50 , half-maximal effective concentration; IC 50 , half-maximal inhibitory concentration.
a Spironolactone is an agonist of the progesterone receptor and the respective EC 50 value is therefore given.
Rationale and design of ARTS the pharmacokinetics of BAY 94-8862 in plasma after multiple oral doses will be assessed.
Patients
Adult males and females without childbearing potential with a clinical diagnosis of HFREF [New York Heart Association (NYHA) class II -III], treated with evidence-based therapy for HFREF, and who meet all of the inclusion criteria and none of the exclusion criteria ( Table 2 ) will be eligible for enrolment in the study. Patients must be withdrawn from the study if: they decline to participate further; continuation of the study would be harmful to the patient's well-being in the opinion of the investigator; it is specifically requested by the sponsor; overall study drug intake is , 80% or .120% of the prescribed dose; any adverse event (AE) occurs that is not acceptable in the opinion of the investigator and/or patient; or the patient develops worsening cardiac function that requires hospitalization and initiation of intravenous drug treatment. In addition, if serum potassium is between 5.5 and 6.0 mmol/L, a second blood sample must be taken as soon as possible, at the latest on the next day. If serum potassium is still . 5.5 mmol/L in the second sample, the study drug must be discontinued permanently. If serum potassium is . 6.0 mmol/L in any blood sample, the study drug must be discontinued permanently without any further laboratory assessment.
Study medication
BAY 94-8862 is administered as oral, immediate-release tablets. In both parts of the study, eligible patients are randomized in the 14 days following a screening visit, and receive the study drug for 4 weeks. In part A, eligible patients were randomized 1:1:1:1 to receive BAY 94-8862 at 2. Treatment with evidence-based therapy for HFREF is a requirement for inclusion in the study ( Table 2 ) and may be continued during the course of the study, apart from the exceptions noted below. Concomitant medications not allowed during the study (from initiation of study drug treatment until the follow-up visit has been completed) include: any aldosterone antagonist or renin inhibitor; use of an ACE inhibitor with an ARB; potassium-sparing agents such as potassium-sparing diuretics; high-dose acetylsalicylic acid (.500 mg/day); daily treatment with non-steroidal anti-inflammatory agents; potent cytochrome P450 (CYP) isoenzyme 3A4 inhibitors or inducers; and strong CYP2C8 inhibitors such as gemfibrozil.
Investigations
Participating patients are assessed at the screening visit, at baseline/day 1 (start of study drug administration), day 4 + 1, day 8 + 1, and weekly thereafter until the end of the study. A follow-up visit will be scheduled 14 days after the last intake of study medication. Patients who discontinue the study prematurely are also assessed as soon as possible after discontinuation. In part B, patients receiving spironolactone at the up-titrated dose of 50 mg o.d. are assessed at an additional visit on day 18 + 1.
Details of the assessments made at each visit are shown in Table 3 . Briefly, patients undergo a physical examination at the screening visit, and demographic data and the medical history are also recorded. Continuous assessment of AEs starts immediately ; moderate, eGFR 30 -60 mL/min/1.73 m after signing the informed consent form until the follow-up visit or the premature discontinuation visit (if applicable). For each AE, the investigator records the maximum intensity (mild, moderate, or severe), seriousness, relationship to the study drug, any actions taken, and the final outcome. At intervals during the course of the study, concomitant medications are noted and vital signs (heart rate and blood pressure) and 12-lead electrocardiograms (ECGs) are assessed after resting for at least 10 min. In addition, blood samples for pharmacokinetic analysis are taken at pre-specified time points. In each case, the time of study drug intake and the sampling time will be recorded. The plasma concentrations of BAY 94-8862 are determined using a sparse sampling approach in all participants.
Study organization
Data from part A were reviewed for safety and tolerability by an independent data monitoring committee (DMC) in August 2011. The safety and tolerability of different doses in patients with HFREF and mild CKD were confirmed by the DMC. Part B was started in patients with HFREF and moderate CKD at the beginning of September 2011.
Statistical considerations Statistical methodology
There will be four analysis sets: the safety set (all patients who have taken at least one dose of study drug); the full analysis set (all individuals from the safety set with baseline and at least one post-baseline serum potassium values); the per protocol set (all patients from the full analysis set of part B with valid serum potassium data at visit 6 or 7 and no major protocol deviations); and the pharmacokinetic analysis set (all patients who complete the study without major protocol deviations). In part A, all variables will be analysed descriptively in the safety set. In part B, the primary analysis will be performed in the full analysis set, with a supportive analysis in the per protocol set.
The primary safety variable in part B will be the change in mean serum potassium values from baseline at visits 6 and 7. Five different dose-response models [linear, quadratic, exponential, logistic, or maximum effect (E max )] will be fitted to the serum potassium data from the placebo and BAY 94-8862 groups, and the best model will be selected based on the Akaike and Bayesian information criteria.
Based on the selected dose-response model, the 95% confidence interval (CI) will be constructed, and the BAY 94-8862 dose range that increases serum potassium concentration more than placebo but less than spironolactone will be identified. An exploratory statistical comparison will be performed between the BAY 94-8862 dose groups that are within this range and the spironolactone group.
In addition, changes in biomarkers, eGFR (MDRD formula), albuminuria, serum potassium and magnesium concentrations, blood pressure, and heart rate will be assessed using analysis of covariance. The numbers of patients with serum potassium concentrations .5.5 mmol/L and 6.0 mmol/L will be analysed by Fisher's exact test. The analyses for the above secondary variables will be performed in the full analysis set and per protocol analysis set; all other safety analyses will be performed in the safety set. Based on a sparse sampling approach performed at multiple visits, the pharmacokinetics of BAY 94-8862 will be analysed using population-pharmacokinetic methods. Safety laboratory parameters and ECG data will be analysed descriptively only.
Sample size
A normally distributed data set with a common standard deviation of serum potassium of 0.5 mmol/L (based on literature research) and mean values that have a linear relationship with the dose was simulated for a sample size of 60 patients in the placebo group and each BAY 94-8862 treatment group. A linear line was fitted and the 95% CI was constructed. For the given sample size, the width of the one-sided 95% CI was 0.08 mmol/L. For the exploratory comparison of the BAY 94-8862 dose groups with the spironolactone group, assuming a common standard deviation of 0.5 mmol/L for change in serum potassium concentration and 60 patients per group, each comparison will have 80% power to detect a difference between the BAY 94-8862 dose group and the spironolactone group.
Ethical considerations
The procedures set out in this protocol pertaining to the conduct, evaluation, and documentation of this study are designed to ensure that the sponsor and investigator abide by Good Clinical Practice guidelines and follow the guiding principles detailed in the Declaration of Helsinki. The study is carried out in keeping with applicable local law(s) and regulation(s). Documented approval from appropriate independent ethics committee(s) or institutional review board(s) was obtained for all participating centres/countries before the start of the study.
Discussion
In order to avoid or at least diminish the untoward side effect of hyperkalaemia associated with currently available MRAs, drugs with a more pronounced cardiac or vascular activity, at least in comparison with the available steroidal MRAs, are desirable so that improvements in cardiac function can be achieved without deleterious changes to sodium-potassium homeostasis in the kidney. Screening for novel non-steroidal MRAs led to the identification of dihydropyridine-based compounds such as BR-4628, which occupies the MR ligand-binding cavity differently from classical steroidal MRAs. 25 A medicinal chemistry optimization programme culminated in the identification of BAY 94-8862, 26 which is at least as potent as spironolactone, even more selective than eplerenone ( Table 1) , and has no residual L-type calcium channel blocking activity, in contrast to related dihydropyridine-based MRAs. 26 -28 The physicochemical properties that drive binding to plasma proteins, tissue permeability, and distribution of this novel compound may lead to a more favourable balance of cardiac antiremodelling effects vs. renal (electrolyte) effects compared with approved MRAs, ultimately leading to an improved clinical safety profile with a reduced risk of hyperkalaemia. ARTS has been designed to address several key questions related to the potential efficacy and safety of BAY 94-8862. The inclusion of both a placebo group and a positive control group treated with spironolactone (25-50 mg o.d.) should allow insight into the relative effects of BAY 94-8862 on renal function and the incidence of hyperkalaemia in patients with HFREF and moderate CKD treated with standard therapy (including an ACE inhibitor or ARB, a beta-blocker, and diuretics), many of whom are expected to have concomitant diabetes mellitus. The open-label nature of the spironolactone treatment will have to be considered when interpreting the results, because investigators may reduce potassium more in the spironolactone group than in the other four groups.
It has been suggested that MRAs may have beneficial effects on the kidneys in patients with CKD. A systematic review of clinical studies in patients with CKD found that addition of MRAs to standard therapy led to a reduction in proteinuria compared with placebo, although a significant improvement in eGFR was not observed. 11 There has not, however, been a large trial powered to evaluate renal and cardiovascular outcomes in patients with CKD, due to the fear of inducing serious hyperkalaemia with the presently available MRAs. A retrospective analysis of almost 25 000 veterans in the USA found that the incidence of hyperkalaemia (serum potassium .5.5 mmol/L) was more than three times higher in patients with CKD than in those without CKD, regardless of renin -angiotensin -aldosterone system inhibitor status, and that there was an increased mortality associated with a serum potassium concentration . 5.5 mmol/L within 24 h of its occurrence. 29 To ensure the safety of BAY 94-8862 and its proposed dosing in ARTS, patients with HFREF and mild CKD (part A) were evaluated and monitored by the DMC before patients with HFREF and moderate CKD were entered into the study (part B). In ARTS, renal effects of BAY 94-8862 are monitored by several parameters including serum creatinine, eGFR, the urinary albumin:-creatinine ratio, and exploratory biomarkers of renal injury, such as NGAL and KIM-1. Effects on cardiac function and injury will also be assessed by monitoring the concentrations of various biomarkers including BNP, NT-proBNP, and ultrasensitive troponin I. The duration of the treatment period (4 weeks) and the follow-up after termination of study medication (14 days) should allow an assessment of the optimal effectiveness of BAY 94-8862 on the MR.
In addition to assessing safety and effects on markers of end-organ function and injury, ARTS will provide information on the pharmacokinetic properties of BAY 94-8862 and its optimal dosing in patients with HFREF and CKD. The study has been designed to determine doses of BAY 94-8862 that cause a significantly lower increase in serum potassium and incidence of hyperkalaemia than spironolactone (25-50 mg o.d.), while having significantly greater efficacy than placebo and at least similar efficacy to spironolactone, as assessed by levels of BNP or NT-proBNP, ultrasensitive troponin I, ADMA, galectin-3, and osteopontin. The relative potency at the MR may be assessed indirectly by measuring the changes in aldosterone levels. In patients with HFREF and CKD, these biomarkers should provide initial insight into the relative effects of BAY 94-8862 on collagen formation, ventricular remodelling, and nitric oxide availability, all of which have been associated with cardiovascular mortality in patients with HFREF and/or CKD.
Conclusion
Heart failure remains a highly prevalent disease with high mortality despite current treatment. The presently available steroidal MRAs spironolactone and eplerenone have been shown to improve outcomes, but adverse effects and the need for frequent monitoring of serum potassium and renal function throughout treatment have limited their uptake in routine clinical practice. Several potential new indications for MRAs are yet to be systematically investigated. BAY 94-8862 is a novel non-steroidal MRA that could potentially combine high potency (similar to spironolactone) with high selectivity (greater than eplerenone), improved end-organ protective activity, and improved safety compared with previous MRAs, based on differences in physicochemical properties. ARTS-a multicentre, randomized, double-blind, placebo-controlled study-is the first clinical trial of BAY 94-8862 in patients and is expected to provide a wealth of information on BAY 
